Preclinical Testing of a New MR Imaging Approach to Distinguish Aggressive from Indolent Disease
Abstract
The goal of this project is to develop a new MRI approach to characterize aggressive cancers based on their genetic/proteomic and perfusion abnormalities and apply this method in preclinical models to obtain the required preliminary data for FDA approval for future clinical trials. The initiation and first year of this project have gone extremely well accomplishing the technical milestones described in the original approved Statement of Work (SOW). No changes in the SOW were needed (or done). In this first year, the technical developments were accomplished and transgenic mouse model studies were initiated. Following the technical development phase, we have initiated the preclinical studies in the transgenic model of prostate cancer studying both Early Stage and Late Stage cancers. Over the past 6 months we have tested and optimized the techniques in vivo and to date have studied a total of nine mice. The initial results demonstrate feasibility and support the hypothesis that this new approach could distinguish aggressive from indolent prostate cancer. Now that we have the techniques working well, we are confident that we can complete the proposed number of studies by the end of the project.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2014
- Accession Number
- ADA608028
Entities
People
- Daniel Vigneron
Organizations
- University of California, San Francisco